Claims for Patent: 9,566,331
✉ Email this page to a colleague
Summary for Patent: 9,566,331
Title: | Vaccine immunotherapy |
Abstract: | A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-.alpha., and IFN-.gamma., and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system. |
Inventor(s): | Hadden; John W. (Cold Spring Harbor, NY), Signorelli; Kathy L. (Kings Park, NY), Egan; James E. (Stony Brook, NY), Naylor; Paul H. (Lindenhurst, NY) |
Assignee: | IRX Therapeutics, Inc. (New York, NY) |
Application Number: | 13/771,622 |
Patent Claims: | 1. A composition for use in eliciting an immune response in a patient, the composition comprising: (a) a primary cell-derived biologic including IL-1, IL-2, IL-6, IL-8,
TNF-.alpha., and IFN-.gamma., and (b) a vaccine comprising a viral vector encoding at least one antigen, wherein the viral vector is a retrovirus, adenovirus, adeno-associated virus (AAV), herpes virus, or poxvirus.
2. The composition of claim 1, wherein the viral vector is a poxvirus and wherein the poxvirus is a vaccinia, modified vaccinia Ankara (MA), NYVAC, avipox, TROVAX, fowlpox, or canarypox. 3. The composition of claim 2, wherein the poxvirus is a canarypox. 4. The composition of claim 3, wherein the canarypox is ALVAC or ALVAC(2). 5. The composition of claim 1, wherein the at least one antigen is at least one tumor associated antigen. 6. The composition of claim 1, further comprising one or more co-stimulatory molecules. 7. The composition of claim 6, wherein the one or more co-stimulatory molecules is selected from the group consisting of abatacept, belatacept, CD28-SuperMAB, a B7/CD28 co-stimulatory molecule, a TNF superfamily co-stimulatory molecule, and a SLAM family co-stimulatory molecule. 8. The composition of claim 1, wherein the viral vector further encodes LFA-1, ICAM-1, and B7.1, or combination thereof. 9. The composition of claim 8, wherein the viral vector encodes LFA-1, ICAM-1, and B7.1. 10. The composition of claim 1, wherein the viral vector encodes one or more proteins which lead to over-expression of co-stimulatory proteins in the patient. 11. A method of vaccination, the method comprising: administering a composition comprising a primary cell-derived biologic including IL-1, IL-2, IL-6, IL-8, TNF-.alpha., and IFN-.gamma. to a patient; and administering a vaccine comprising a viral vector encoding at least one antigen to the patient, wherein the viral vector is a retrovirus, adenovirus, adeno-associated virus (AAV), herpes virus, or poxvirus. 12. The method of claim 11, wherein the viral vector is a poxvirus and wherein the poxvirus is a vaccinia, modified vaccinia Ankara (MA), NYVAC, avipox, TROVAX, fowlpox, or canarypox. 13. The method of claim 12, wherein the poxvirus is a canarypox. 14. The method of claim 13, wherein the canarypox is ALVAC or ALVAC(2). 15. The method of claim 11, wherein the method further comprises administering abatacept, belatacept, CD28-SuperMAB, a B7.CD28 co-stimulatory molecule, a TNF superfamily co-stimulatory molecule, a SLAM family co-stimulatory molecule, or combinations thereof. 16. The method of claim 11, wherein the method further comprises administering an anti-CTLA-4 antibody. 17. The method of claim 11, wherein the viral vector further encodes LFA-1, ICAM-1, B7.1, or combination thereof. 18. The method of claim 11, wherein the viral vector further encodes LFA-1, ICAM-1, and B7.1. 19. The method of claim 11, wherein the viral vector further encodes one or more proteins which lead to over-expression of co-stimulatory proteins in the patient. |
Details for Patent 9,566,331
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bristol-myers Squibb Company | ORENCIA | abatacept | For Injection | 125118 | 12/23/2005 | ⤷ Try a Trial | 2029-05-15 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 07/29/2011 | ⤷ Try a Trial | 2029-05-15 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 06/07/2016 | ⤷ Try a Trial | 2029-05-15 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 03/30/2017 | ⤷ Try a Trial | 2029-05-15 |
Bristol-myers Squibb Company | NULOJIX | belatacept | For Injection | 125288 | 06/15/2011 | ⤷ Try a Trial | 2029-05-15 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.